Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30518584 | 0.89 | PTPN1 (0.45) | PTPN1GRB2MDM2 | |
| SCHEMBL22265895 | 0.88 | SSTR3 (0.50) | PTPN1KDM1A | |
| SCHEMBL29649620 | 0.87 | PTPN1 (0.42) | PTPN1GRB2MDM2 | |
| SCHEMBL29649613 | 0.86 | PTPN1 (0.42) | PTPN1GRB2MDM2 | |
| SCHEMBL31677955 | 0.84 | MDM2 (0.51) | PTPN1MDM2 | |
| SCHEMBL25361276 | 0.83 | PTPN1 (0.46) | PTPN1SIRT5GRB2MDM2 | |
| SCHEMBL25361270 | 0.83 | PTPN1 (0.46) | PTPN1SIRT5GRB2MDM2 | |
| SCHEMBL31681574 | 0.83 | MDM2 (0.45) | SIRT5MDM2 | |
| SCHEMBL29649526 | 0.83 | MDM2 (0.45) | SIRT5MDM2 | |
| SCHEMBL12683247 | 0.82 | SSTR3 (0.47) | PTPN1GRB2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226490-A1 | Glycoside-Containing Peptide Linkers for Antibody-Drug Conjugates | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-07-21 | — | — | US | disclosed |
| EP-3914262-A1 | GLYCOSIDE-CONTAINING PEPTIDE LINKERS FOR ANTIBODY-DRUG CONJUGATES | R.P. Scherer Technologies, LLC (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020154437-A1 | GLYCOSIDE-CONTAINING PEPTIDE LINKERS FOR ANTIBODY-DRUG CONJUGATES | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226490-A1 | Glycoside-Containing Peptide Linkers for Antibody-Drug Conjugates | DNPEP, VIP, SI | PTPN1 1937/4885SIRT5 1513/4885GRB2 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.